Covid-19 treatment trial for kidney patients goes national
An Addenbrooke’s trial is rolling out to hospitals across the UK to see if a drug used to treat tapeworm can give high-risk kidney patients extra protection against Covid-19.
Trials Methodologist, CCTU
Senior Research Fellow, University of Cambridge
Consultant Nephrologist, CUH NHS Foundation Trust
The PROTECT-V study has been running since February and now 40 more hospitals will join in to investigate whether niclosamide can reduce the number of people who become seriously ill or die.
If the trial is successful, it may pave the way for a new treatment to prevent or alleviate the impact of Covid-19 in people on dialysis, kidney transplant patients, and those with auto-immune diseases affecting the kidneys, such as vasculitis.
Addenbrooke’s consultant nephrologist and University of Cambridge senior research associate, Dr Rona Smith, is heading the UK study into whether niclosamide can protect people on its own, or in combination with other drugs.
The trial is recruiting at least 1,500 kidney patients across the UK, who will receive either a placebo or niclosamide as a nasal spray, both provided by the manufacturer, UNION therapeutics. Additional promising drugs could be added in the future,
Kidney patients should continue to have the vaccine, as soon as they are offered it. Those who have had a kidney transplant must continue taking their immunosuppressant drugs, despite these making them more susceptible to infection.
Kidney patients who would like to take part in PROTECT-V should speak to their nephrologist in their local centre . More information is available via https://www.camcovidtrials.net/trials/view,protectv_50.htm
The trial, led by the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, is funded by LifeArc, Kidney Research UK, the Addenbrooke’s Charitable Trust and UNION therapeutics and is supported by the NIHR Cambridge Biomedical Research Centre. UNION therapeutics is supplying the drug.
For more information visit: CUH News
Published June 24 2021
Latest from CCTU
National Patient Led Research Hub celebrates tenth anniversary
A national team based in Cambridge are celebrating ten years of helping people living with rare diseases to develop their own research ideas. The hub has…
Hope for MS patients as Cambridge trial suggests drug combination may repair nerve damage
Early findings from a clinical trial in Cambridge suggest a combination of metformin, a diabetes drug, and clemastine, an antihistamine, can help repair…
Prospective study into controversial brain cyst syndrome is world first
The world’s first study of its kind highlights the potential value of surgery to treat a specific kind of brain cyst that blights the lives of patients.
